Last reviewed · How we verify
Dapiprazole Hydrochloride (DAPIPRAZOLE)
At a glance
| Generic name | DAPIPRAZOLE |
|---|---|
| Sponsor | Fera Pharms |
| Drug class | alpha-Adrenergic Blocker |
| Target | Alpha-1D adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
- Reverse Mydriasis from Ophthalmic Adrenergic or Anticholinergic Agent
Common side effects
- Conjunctival injection
- Burning on instillation
- Ptosis
- Lid erythema
- Lid edema
- Chemosis
- Itching
- Punctate keratitis
- Corneal edema
- Browache
- Photophobia
- Headaches
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dapiprazole Hydrochloride CI brief — competitive landscape report
- Dapiprazole Hydrochloride updates RSS · CI watch RSS
- Fera Pharms portfolio CI